The phase 2 GO29781 study showed that 80% of patients who had received at least 2 prior therapies achieved durable response rates with mosunetuzumab-axgb treatment.
The FDA approved lenacapavir, which is the first approval of a drug in a new class of antiretrovirals for the treatment of HIV-1 called capsid inhibitors.
The FDA's approval includes the group indication for all current and future EGFR TKIs, including erlotinib, osimertinib, and gefitinib.
HOPA DEI Committee chair Kamakshi Rao, PharmD, BCOP, FASHP, noted that on the DEI journey ahead, the oncology pharmacist should be front and center as part of the treatment team.
An anti-cancer vaccine that is now in clinical trials shows promise as a preventative agent. However, experts are unsure when it will be widely available.
All primary and ranked secondary endpoints of the study were met at week 16, which were sustained or improved through week 24 and were coupled with patient-reported improvements compared with placebo in treating psoriatic arthritis.
Financial assistance platforms improve patient outcomes and the pharmacy bottom line.
Lack of access to novel therapies, especially within the cancer space, initiated the road to patient navigation.
The additional indication expands its therapeutic role beyond advanced non-small cell lung cancer.
Adalimumab-aacf (Idacio) is indicated for chronic conditions such as rheumatoid arthritis, plaque psoriasis, ulcerative colitis, psoriatic arthritis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
E7777 is an engineered interleukin-2-diphtheria toxin fusion protein that is a purified and more bioactive formulation of Ontak, which the agency previously approved.
Following the positive phase 3 results, GSK anticipates regulatory submissions in the first half of 2023.
Despite the increasing approval of neurological medications, just a small percentage of individuals are using them because of skyrocketing out-of-pocket expenses.
Despite a limited understanding about access to oral anticancer drugs, new research finds challenges in patient and clinician decision-making.
Expert discusses the patient-reported outcomes from the GRIFFIN trial at the final study analysis after all patients completed 1 year of follow-up post maintenance therapy.
Expert discusses updated cohort of patients with longer-term follow up treated in the phase 2 clinical trial of venetoclax added to cladribine plus low-dose araC alternating with azacytidine.
Expert discusses the updated data for a trial cohort after a median follow-up of 27 months.
Based on real-world outcomes, there is an unmet need for an effective therapy to be used among patients aged 75 years or older with relapsed/refractory diffuse large B-cell lymphoma.
Five crucial steps pharmacies can take to enhance patient engagement and lower operational costs.
Expert discusses the effect of baseline transfusion burden and luspatercept dose level on response to treatment in patients with LR-MDS from the MEDALIST study.
Expert discusses the results of a trial assessing immune reconstitution in adult patients who received Orca-T, consisting of hematopoietic stem/progenitor cells, regulatory T cells, and conventional T cells.
Expert discusses the safety and efficacy of polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) as second-line treatment in a multicenter phase 2 study.
Expert discusses analysis of phase 3 MEDALIST trial data aimed to assess the probability of greater overall survival and progression-free survival benefit from luspatercept vs placebo.
In recent decades, clinical trials have grown increasingly restrictive and exclusive, which has impacted the inclusivity and diversity of selected trial participants.
Mice receiving prophylactic recombinant factor FVIII and intravenous immunoglobulin for hemophilia A had reduced anti-FVIII antibodies versus mice who received FVIII only.
New system may more accurately identify IVIG resistance in North American patients with Kawasaki disease than the Kobayashi score.
Teplizumab is a humanized IgG1κ Fc-nonbinding anti-CD3 monoclonal antibody that blocks T cells, preventing them from attacking beta cells.
The allogeneic CAR-T cell therapy is in development for relapsed or refractory large B cell lymphoma and relapsed or refractory B cell non-Hodgkin lymphoma.
With the advent of disease-modifying therapies, the life span of patients with multiple sclerosis has increased dramatically.
Treatment with immune checkpoint inhibitors have the potential for immune-related adverse events, such as psoriasis.
